These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37146908)

  • 1. How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
    Zeifman RJ; Wagner AC; Monson CM; Carhart-Harris RL
    J Affect Disord; 2023 Aug; 334():100-112. PubMed ID: 37146908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation.
    Zeifman RJ; Wagner AC; Watts R; Kettner H; Mertens LJ; Carhart-Harris RL
    Front Psychiatry; 2020; 11():782. PubMed ID: 32903724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.
    Watts R; Kettner H; Geerts D; Gandy S; Kartner L; Mertens L; Timmermann C; Nour MM; Kaelen M; Nutt D; Carhart-Harris R; Roseman L
    Psychopharmacology (Berl); 2022 Nov; 239(11):3461-3483. PubMed ID: 35939083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obsessive-Compulsive Disorder and Suicidal Experiences: The Role of Experiential Avoidance.
    Angelakis I; Gooding P
    Suicide Life Threat Behav; 2020 Apr; 50(2):359-371. PubMed ID: 31553082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.
    Barba T; Buehler S; Kettner H; Radu C; Cunha BG; Nutt DJ; Erritzoe D; Roseman L; Carhart-Harris R
    BJPsych Open; 2022 Sep; 8(5):e163. PubMed ID: 36065128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
    Agin-Liebes G; Davis AK
    Curr Top Behav Neurosci; 2022; 56():125-140. PubMed ID: 34811715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.
    Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J
    Curr Psychiatry Rep; 2022 Oct; 24(10):573-581. PubMed ID: 35953638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reductions in experiential avoidance explain changes in anxiety, depression and well-being after a mindfulness and self-compassion (MSC) training.
    Yela JR; Crego A; Buz J; Sánchez-Zaballos E; Gómez-Martínez MÁ
    Psychol Psychother; 2022 Jun; 95(2):402-422. PubMed ID: 34904363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
    Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.
    Nayak SM; Bari BA; Yaden DB; Spriggs MJ; Rosas FE; Peill JM; Giribaldi B; Erritzoe D; Nutt DJ; Carhart-Harris R
    Psychedelic Med (New Rochelle); 2023 Mar; 1(1):18-26. PubMed ID: 37337526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.
    Gill H; Puramat P; Patel P; Gill B; Marks CA; Rodrigues NB; Castle D; Cha DS; Mansur RB; Rosenblat JD; McIntyre RS
    Psychiatry Res; 2022 Jul; 313():114577. PubMed ID: 35580433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.
    Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Psychol Med; 2024 Jan; 54(1):178-192. PubMed ID: 37264814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiential Avoidance Predicts Persistence of Major Depressive Disorder and Generalized Anxiety Disorder in Late Adolescence.
    Mellick WH; Mills JA; Kroska EB; Calarge CA; Sharp C; Dindo LN
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31644841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS; Reines EH; Guiton C; Weiller E
    Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in Experiential Avoidance is Associated with Reduced Suicidal Ideation over the Course of Psychiatric Hospitalization.
    Ellis TE; Rufino KA
    Arch Suicide Res; 2016 Jul; 20(3):426-37. PubMed ID: 27046328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.